Moderna is offering to share ownership of its COVID-19 vaccine patent with the U.S. government to resolve the dispute, the vaccine maker said, and would allow the Biden administration to "license ...

Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 ...

U.S. National Institutes of Health scientists played "a major role" in developing Moderna Inc's COVID-19 vaccine and the agency intends to defend its claim as co-owner of patents on the shot, NIH ...

Pfizer (PFE) and BioNTech (BNTX) challenge Moderna's patent win in London court over mRNA COVID-19 vaccine technology. Read ...

As COVID vaccine patent dispute drags on, Moderna forks over $400M to NIH Moderna called the sum a "catch-up payment" for borrowing a molecular technique.

Moderna’s COVID-19 vaccine is at the centre of a patent dispute that could potentially affect future public–private collaborations. Credit: Moch Farabi Wardana/Pacific Press/LightRocket/Getty ...

Moderna is pausing a patent dispute with the federal government over its groundbreaking coronavirus vaccine, saying it is “grateful” to government scientists who collaborated with the company ...

A legal battle between rival developers of Covid-19 jabs over vaccine technology patents has produced a mixed ruling from a High Court judge. Pharmaceutical giant Pfizer and drug manufacturer ...

Moderna stock falls 2.32% due to patent infringement suit. However, some investors see this as an opportunity to enter or average out. Golden Cross formation also offers hope for future growth.

Amid growing calls for wealthier nations to help make vaccines more widely available worldwide, Moderna and the National Institutes of Health find themselves immersed in a dispute over credit for a ...

Moderna Inc MRNA has reportedly achieved a significant victory at the European Patent Office (EPO) in its ongoing legal battle with Pfizer Inc PFE and BioNTech SE BNTX over the Covid-19 vaccine. ...

While money from Covid vaccine sales is a key driver of the dispute, the patent battle could prove influential for the development of future mRNA-based products.